 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
5 News |  |
- || depatuxizumab mafodotin (ABT-414) / AbbVie, losatuxizumab vedotin (ABBV-221) / AbbVie
PK/PD data, Journal: Bystander effects, pharmacokinetics, and linker-payload stability of EGFR-targeting antibody-drug conjugates Losatuxizumab vedotin and Depatux-M in glioblastoma models. (Pubmed Central) - May 15, 2024
EGFR-targeting ADCs are promising therapeutic options for GBM when delivered intra-tumorally by CED. However, the linker and payload for the ADC must be carefully considered to maximize the therapeutic window.
- depatuxizumab mafodotin (ABT-414) / AbbVie, losatuxizumab vedotin (ABBV-221) / AbbVie
Efficacy and pharmacokinetics of EGFR-targeted antibody-drug conjugates following convection-enhanced delivery in mice with glioblastoma xenografts (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_391;
However, high concentrations of ABBV-221 are associated with increased neuronal cell loss and toxicity as compared to Depatux-M, suggesting a broader therapeutic window for the latter ADC. Median survival, daysTreatmentGBM6GBM39GBM108AB095 – CED 4920NRAB095-MMAF – CED >80 58 18.5 Depatux-M – IP 57 68 NR Depatux-M – CED >80 >100 NR AB095-MMAE – CED 57 19 NR ABBV-221 – IP 53 >100 NR ABBV-221 – CED >80 >100 NR No
- || losatuxizumab vedotin (ABBV-221) / AbbVie
Clinical, P1 data, PK/PD data, Journal: A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. (Pubmed Central) - Sep 4, 2021
The high frequency of infusion reactions necessitated early closure of this trial. The detailed mitigation strategies used in this protocol for infusion-related reactions may provide beneficial information for trial design of agents with high infusion reaction rates.
- | serclutamab talirine (ABBV-321) / AbbVie, depatuxizumab mafodotin (ABT-414) / AbbVie, losatuxizumab vedotin (ABBV-221) / AbbVie
Journal: Targeting Multiple EGFR Expressing Tumors with a Highly Potent Tumor-Selective Antibody Drug Conjugate. (Pubmed Central) - Aug 8, 2021
Collectively, these data suggest that ABBV-321 may offer an extended breadth of efficacy relative to other EGFR ADCs while extending utility to multiple EGFR-expressing tumor indications. Despite its highly potent PBD dimer payload, the tumor selectivity of ABBV-321 - coupled with its pharmacology, toxicology and pharmacokinetic profiles - support continuation of ongoing Phase 1 clinical trials in patients with advanced EGFR-expressing malignancies.
- || depatuxizumab (ABT-806) / AbbVie, Life Science Pharma
Clinical, Journal: Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. (Pubmed Central) - Oct 8, 2020
We demonstrated the specific targeting of the mAb806 epitope expressing MM tumors using Zr-based PET imaging. Our data suggest that targeting EGFR in MM using specific ADCs is a valid therapeutic strategy and supports further investigation of the mAb806 epitope expression as a predictive biomarker.
- | losatuxizumab vedotin (ABBV-221) / AbbVie
Journal: Characterization of ABBV-221, a Tumor-Selective EGFR Targeting Antibody Drug Conjugate. (Pubmed Central) - Jun 22, 2019
ABBV-221 has similar activity as depatux-m against an EGFR amplified GBM PDX model and is highly effective alone and in combination with standard of care (SOC) temozolomide in an EGFRvIII positive GBM xenograft model. Based on these results, ABBV-221 has advanced to a phase 1 clinical trial in patients with advanced solid tumors associated with elevated levels of EGFR.
- losatuxizumab vedotin (ABBV-221) / AbbVie
Trial completion date, Trial termination, Metastases: A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor (clinicaltrials.gov) - Mar 27, 2018
P1, N=46, Terminated, Sponsor: AbbVie
Based on these results, ABBV-221 has advanced to a phase 1 clinical trial in patients with advanced solid tumors associated with elevated levels of EGFR. Trial completion date: Nov 2018 --> Mar 2018 | Active, not recruiting --> Terminated; Safety
- losatuxizumab vedotin (ABBV-221) / AbbVie
Enrollment closed, Enrollment change, Metastases: A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor (clinicaltrials.gov) - Feb 5, 2018
P1, N=45, Active, not recruiting, Sponsor: AbbVie
Trial completion date: Nov 2018 --> Mar 2018 | Active, not recruiting --> Terminated; Safety Recruiting --> Active, not recruiting | N=90 --> 45
- || losatuxizumab vedotin (ABBV-221) / AbbVie
Enrollment change, Metastases: A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor (clinicaltrials.gov) - Apr 21, 2016
P1, N=80, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting | N=90 --> 45 N=56 --> 80
- ||| losatuxizumab vedotin (ABBV-221) / AbbVie
New P1 trial, Metastases: A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor (clinicaltrials.gov) - Feb 19, 2015
P1, N=56, Recruiting, Sponsor: AbbVie